DiamiR Announces Poster Presentation on Detection and Differentiation of Neurodegenerative Diseases at the Biomarkers & Diagnostics World Congress 2014

MONMOUTH JUNCTION, NJ--(Marketwired - April 28, 2014) - DiamiR, LLC, a molecular diagnostics company focused on the development and commercialization of innovative blood-based tests for detection and monitoring of neurodegenerative diseases and cancer, announced today that the company's CEO, Dr. Kira Sheinerman, will participate in the 10th Biomarkers & Diagnostics World Congress in Philadelphia, PA and will present clinical data and analysis of circulating brain-enriched microRNAs for detection and differentiation of Mild Cognitive Impairment, Alzheimer's and Parkinson's diseases.

Title: Analysis of Brain-enriched microRNA Biomarkers in Plasma for Early Detection of Neurodegenerative Diseases
Track: Biomarkers for Patient Selection
Dates: April 30 - May 1, 2014
Location: Loews Philadelphia Hotel, Exhibit Hall
Poster Number: 10

About microRNAs as biomarkers of brain health

microRNAs (miRNAs) are a class of non-coding functional RNA molecules modulating target gene expression and protein production. Many miRNAs are enriched in certain organs (e.g. brain), tissues or organ regions (e.g. hippocampus, midbrain), cell types (e.g. neurons), and cellular compartments (e.g. synapses and neurites). Due to their small size (~22 nucleotides), miRNAs can cross the blood-brain barrier and appear in the bloodstream. Thus, the properties of brain-enriched miRNAs make them suitable biomarkers of brain health detectable in systemic circulation.

About DiamiR, LLC

DiamiR, LLC is a privately held molecular diagnostic company focused on developing noninvasive tests for early detection and monitoring of Mild Cognitive Impairment, Alzheimer's disease, other neurodegenerative diseases, and cancer. The proprietary technology is based on quantitative analysis of circulating organ-enriched microRNAs in plasma and can be used for screening, patient stratification as well as disease and treatment monitoring. For more information, please visit the company's website at www.diamirbio.com.

Please Note: This news release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: the results, timing, costs and regulatory review of our studies and clinical trials; the results of studies of our product candidates conducted by others; our ability to obtain future funding on acceptable terms; our ability to obtain regulatory approval of our product candidates; the possible impairment of, or inability to obtain, intellectual property rights; and innovation by our competitors.